Imfinzi (Durvalumab) Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Imfinzi Injection contains durvalumab, a monoclonal antibody that binds PD-L1. Its labelling describes it as an immunotherapy for several cancers — including non-small cell lung cancer, small cell lung cancer, biliary tract (bile duct) cancer, liver cancer and endometrial cancer — described as helping the immune system recognise and attack cancer cells.
Product Information
The following description reflects information associated with durvalumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of non-small cell lung cancer
- Described for the treatment of small cell lung cancer
- Described for the treatment of biliary tract cancer
- Described for the treatment of liver cancer (hepatocellular carcinoma)
- Described for the treatment of endometrial cancer
- Often described as used in combination with chemotherapy or other agents
Described Dosage & Administration
- Administered only by a healthcare professional as an intravenous infusion
- Given at the interval set by the treating specialist; the schedule should be followed as directed
- A full medical history, including autoimmune conditions, should be shared with the doctor
Described Side Effects
Commonly described side effects include:
- Cough and breathlessness
- Nausea and diarrhoea
- Fatigue
- Rash and itching
- Musculoskeletal pain
- Abdominal pain
- Upper respiratory tract infection
- Described as possibly causing immune-related inflammation of the lungs, bowel, liver or glands (pneumonitis, colitis, hepatitis, endocrine effects)
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Described as generally not recommended in people with certain active autoimmune conditions
- New or worsening cough, breathlessness, diarrhoea, jaundice or fatigue should be reported promptly
- Pregnancy or breastfeeding should be discussed with the prescriber
- Other medicines being taken should be disclosed to avoid interactions
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains durvalumab, a PD-L1 blocking antibody, and is described for several cancers including lung, biliary tract, liver and endometrial cancer. SDO Pharma has not independently verified these claims.
Its labelling describes an intravenous infusion given by a healthcare professional.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.